Both ATR and CDC7 inhibitors (ATRis and CDC7is) show excellent anti-tumor activity in a variety of preclinical cancer models and are currently being explored as potential anti-cancer agents in clinical trials.22 The gene discussed is CDC7; the disease is neoplasm.